CA2104686C - Delayed release oral dosage forms for treatment of intestinal disorders - Google Patents
Delayed release oral dosage forms for treatment of intestinal disorders Download PDFInfo
- Publication number
- CA2104686C CA2104686C CA002104686A CA2104686A CA2104686C CA 2104686 C CA2104686 C CA 2104686C CA 002104686 A CA002104686 A CA 002104686A CA 2104686 A CA2104686 A CA 2104686A CA 2104686 C CA2104686 C CA 2104686C
- Authority
- CA
- Canada
- Prior art keywords
- dosage form
- drug
- granules
- coating
- coated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/245—Bismuth; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/52—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
An orally administrable pharmaceutical dosage form for selectively administering a drug to the intestine comprises a plurality of enteric coated granules of the drug contained in an enterically coated capsule which releases the granules in the small intestine. The granules are preferably coated with a coating which remains intact until the coated granules reach at least the ileum and thereafter provide a sustained release of the drug in the colon. Suitable coating materials are selected from the Eudragit range of (meth)acrylate and (meth)acrylic acid polymers. The invention has particular application to topically active drugs such as topically active steroids, bismuth salts and complexes, and especially, 5amino-salicylic acid.
Description
2 PCT/GB92/00318 DELAYED RELEASE ORAL DOSAGE FORMS
FOR TREATMENT OF INTESTINAL DISORDERS
The present invention relates to the administration of drugs to the intestine and has particular, but not exclusive, application to the treatment of colonic disorders by administration to the ileum and/or colon of drugs such as 5-amino-salicylic acid (hereinafter referred to as 5-ASA).
Treatment of diseases of the intestine usually requires the delivery of a drug to the affected site. When the disease is essentially confined to a specific part of the intestine, such as the colon in ulcerative colitis or Crohn's colitis, it is desirable to target administration of the drug to that part in order to provide and control optimum local concentration of the drug. In this connection, some drugs such as 5-ASA are absorbed or inactivated in the small intestine.
The formulation of a drug in a conventional enteric coated capsule or tablet merely prevents release of the drug until the alkaline environment of the small intestine is reached. The problem of targeting the drug to the colon in an effective and viable manner was not solved until the proposal by the present inventors to coat solid oral dosage forms with a thick; coating of an anionic polymer of defined 2~ p468 6 pH dissolution profile (see EP-A-0097651).
Several "delayed release" forms of orally administrable drugs have been proposed. The delayed release may result from the physical properties of the formulation or from the chemical and physical properties of a derivative of the drug. It is known to provide capsules and tablets with a coating which will disintegrate to release the drug gradually when the capsule or tablet has reached the acid environment of the stomach or the alkaline environment of the small intestine. Similarly, it is known to provide capsules and tablets with a coating permeable to the drug contained and through which the drug is gradually released.
It was proposed in GB-A-1219026 (published January 1971) to embed individual particles of a drug in a slowly disintegrating or slowly dissolving resin matrix having a particular dissolution profile to provide an orally administrable formulation for selectively administering the drug to the large intestine. The resin is selected such that the drug remains substantially protected within the resin matrix while the particles travel through the stomach and small intestine of a patient and that the drug is substantially completely exposed at the time the particles reach the large intestine. In particular, the nature and amount of the resin is selected so that when a quantity of WO 92/14452 . . , . . . " PCT/GB92/00318 "....,, .
- ..2:1.04 8 6 the embedded drug is introduced into a Stoll-Gershberg disintegration apparatus, submerged in a simulated intestinal fluid (made in accordance with the U.S.
Pharmacopoeia, Volume XVII, 1965 at page 919 but modified by containing no pancreatin), and operated as described in the patent specification, 2% to 12% of the drug dissolves within an hour of the introduction of the formulation into the fluid and 18% to 88% of the drug dissolves within three hours of said introduction. It is specifically stated that the resin is selected so that the dissolution rate of the drug is not pH dependent but is time dependent. The preferred resin is a high-viscosity grade modified vinyl acetate resin (available under the Registered Trade Mark "Gelva" C3-V30) and other specified resins are carboxylated polyvinyl acetates, polyvinyl/maleic anhydride copolymers, poly(methacrylic acid), ethylene/maleic anhydride copolymers, ethyl cellulose, methylacrylic acid/methyl methacrylate copolymers, waxes and mixtures thereof including mixtures with shellac. Tablets of the embedded particles coated with a standard coating solution containing cellulose-acetate-phthalate are reported.
It will be appreciated that the carrier system disclosed in GB-A-1219026 relies upon the rate of disintegration or dissolution of the resin as the preparation passes through the gastro-intestinal tract.
The time dependency makes it impossible to limit a WO 92/14452 ~ , PCT/GB92/00318 administration of the drug to the colon because of large variations in the transit time in the gastro-intestinal tract, especially in the stomach, which occur between different patients and in the same patient from time to time. It would appear that the carrier system has not been satisfactory in practice because we are not aware of any relevant product presently available in the UK or elsewhere.
Anionic polymers have been known for many years to be of use in the preparation of coatings for capsules and to provide delayed or sustained release of an encapsulated drug. In particular, it has been known since at least 1974 to use for said coatings anionic copolymers of methacrylic acid and methacrylic acid methyl ester. Such a copolymer (available from Rohm Pharma GmbH, Darmstadt, Germany under the Registered Trade Mark "Eudragit" S) in which the ratio of free carboxyl groups to ester groups is approximately 1:2 and having a mean molecular weight of 135,000 is known to be insoluble in gastric juice and poorly soluble in intestinal juice while an analogous copolymer (available Rohm Pharma GmbH, Darmstadt, Germany under the Registered Trade Mark "Eudragit" L) differing only in so far as said ratio is approximately 1:1 also is insoluble in gastric juice but is readily soluble in intestinal juice. Prior to the invention of EP-A-0097651, said copolymers were usually employed to provide a coating of between 25 and 40 , ~~1- fl468 6 _5_ micrometers thick and the poorly soluble (in intestinal juice) copolymer usually is employed to reduce the dissolution (in intestinal juice) of the readily soluble copolymer. In general terms, except in connection with the invention of EP-A-0097651, anionic polymer coatings on oral dosage forms have been required to dissolve in aqueous medium at a pH below 7, usually between pH 5.5 and pH 7.
Eudragit S dissolves above pH 7 but, as noted above, usually is employed in admixture with Eudragit L. As far as we are aware, said mixtures invariably dissolve below pH
7.
Salicylazosulphapyridine (also known as sulphasalazine or salazopyrin and hereinafter referred to as SASP) consists of sulphapyridine linked to a salicylate group by a diazo bond and has been used for decades in the treatment of colitis, Crohn's disease, idiopathic proctitis and chronic arthritis. Orally administered SASP is only absorbed to a limited extent before reaching the colon where azo-reductases produced by colonic bacteria act to split SASP into sulphapyridine and 5-ASA. Studies by A.K.A. Khan et al (The Lancet, October 29 1977, p. 892) and others have shown the 5-ASA to be the pharmacologically active agent in the treatment of colonic disease with SASP.
Sulphasalazine appears merely to act as a chemical carrier to deliver 5-ASA to the colon. When administere~7 ~rai~~
without the azo-bond joining them, sulphapyridine and 5-ASA
a ~~ X46 8 6 -6_ are almost entirely absorbed from the small intestine before reaching the colon.
Several proposals have been made in recent years for the oral administration of 5-ASA avoiding using SASP in order to reduce the occurrence of side effects attributable to the sulphapyridine moiety. For example, in US-A-4190716 (published February 1980), it was proposed to covalently bond the 5-ASA to a nonabsorbable pharmacologically acceptable organic polymer backbone comprising a plurality of aromatic rings by azo bonds bridging aromatic carbon atoms and the 5-position carbon of 5-ASA.
In GB-A-2021409 (published December 1979), it was proposed that 5-ASA should be administered concurrently or concomitantly with certain disodium cromoglycate-like compounds. Reference is made to formulating 5-ASA in sustained or controlled release form by coating some or all 5-ASA particles or granules thereof with a slowly soluble or digestible or semi- permeable layer of material such as beeswax, Carnauba wax, stearic or palmitic acids or cetyl alcohol. Reference also is made to coating tablets of the coated or uncoated 5-ASA with a continuous film of a material such as shellac or cellulose acetate phthalate which is resistant and impermeable to gastric secretions but susceptible to intestinal secretions. None of the coating materials specified or indicated in the 2'l p488 6 specification are such as to prevent release of 5-ASA until the colon.
WO-A-81/02671 (published October 1981) proposed formulating 5-ASA in a sustained release tablet or enterosoluble tablet form and specifies ethyl cellulose as the preferred coating material. No coating materials other than cellulose derivatives are mentioned and it is granules, as distinct from tablets or other solid oral dosage forms, which are described as being coated. The coating is intended to provide sustained release of 5-ASA
throughout the small and large intestine.
EP-A-0040590 (published November 1981) proposes coating a core of 5-ASA with a coating material comprising at least, (a) 10 to 85o by weight of an anionic carboxylic polymer soluble only above pH 5.5 and (b) 15 to 90% by weight of a water-soluble, quaternary ammonium substituted acrylic polymer. It is stated that the coating normally will be 3 to 60, preferably 10 to 30, micrometers thick and that partly methyl esterified methacrylic acid polymers are suitable anionic carboxylic polymers for use as component (a). In the Examples, Eudragit L and a mixture of Eudragit L and Eudragit S constitute the component (a) and in all cases the coatings dissolved below pH 7. The coated bodies of the EP-A-0040590 are subsequently included in dosage units which normally contain at least 10 coated bodies.
a _8_ 2~ 046s s The rationale of the coating system is stated to be that the change of pH from acid to neutral at the pylorus triggers a change in the physical condition of the coating so that 5-ASA is subsequently released after a predetermined time lag by which time the formulation should have reached the colon. Although time of passage through the small intestine is relatively constant, it still varies from 2 to 5 hours and hence the carrier system does not provide for reliable release of 5-ASA specifically in the colon.
EP-A-0097651 (published February 1983 as WO-A-8300435) disclosed that 5-ASA reliably can be administered specifically to the large intestine, especially the colon, by simply coating a solid oral dosage form with a 60 to 150 micrometers thick layer of an anionic polymer which is insoluble in gastric juice and in intestinal juice below pH
7 but soluble in colonic intestinal juice, whereby the oral dosage form remains intact until it reaches the colon.
This carrier system differs from those previously disclosed in relation to 5-ASA in that dissolution or disintegration does not occur until entry of the coated dosage form into the colon. In particular, there is substantially no leaching out of the 5-ASA downstream of the colon in the normal patient. The carrier system is not limited to 5-ASA
but can be used for other drugs, such as prednisolone methasulphobenzoate, which require to be targeted to the ",..., _ 21 p468 6 colon.
Although the 5-ASA formulation of EP-A-0097651 has found widespread and increasing use in the treatment of ulcerative colitis or Crohn's colitis, there are occasions upon which it would be desirable to avoid the release of a large bolus of 5-ASA or other drug in the colon and to deliver the drug in smaller quantities. instead to give more of a plateau release than the rapid peak absorption caused by bolus releases and to reduce the risk of local irritation. Further, it is desirable to provide a more flexible release system which would permit targeted release in the small intestine instead of in the colon.
Accordingly, we have investigated the possibility of alternative formulations for targeting drugs to the intestine. As a result of those investigations, we have found that the drug can successfully be targeted by replacing the coated oral dosage form of EP-A-0097651 with individually coated granules within an enteric coated capsule.
In its broadest aspect, the present invention provides an orally administrable pharmaceutical dosage form for selectively administering a drug to the intestine comprising a plurality of granules of the drug contained in . a capsule, characterized in that said granules and said capsule are coated with the same or different coating n 2~ p4fi8 6 . . _ -1~-material which dissolves in the intestine.
According to a preferred embodiment, the present invention provides an orally administrable pharmaceutical dosage form for selectively administering a drug to the large intestine comprising a plurality of granules of the drug contained~in an enterically coated capsule which releases the granules in the small intestine, characterized in that said granules are coated with a coating which remains substantially intact until the coated granules reach at least the ileum and, preferably, thereafter provides a sustained release of the drug in the colon.
According to an especially preferred embodiment of the present invention, there is provided an orally administrable pharmaceutical dosage form for selectively administering a drug to the colon comprising a plurality of granules of the drug contained in an enterically coated capsule which releases the granules in the small intestine, characterized in that said granules are coated with a coating material comprising an anionic polymei which is insoluble in gastric juice and in intestinal juice below pH
7 but is soluble in colonic intestinal juice whereby the coating on the released coated granules remains substantially intact until the granules reach at least the ileum and, preferably, thereafter provides a sustained release of the drug in the colon.
Although the invention has particular application to 5-ASA, it can be used to target any desired drug, especially a topically active drug, to the intestine. In particular, it has application to the administration of topically active steroids such as prednisolone metasulphobenzoate to the ileum and/or colon. Other drugs which can be administered by the invention include bismuth salts or complexes, for example bismuth-carbomer complexes.
The relevant drug will be present in the dosage form of the invention in suitable unit dose amounts. Said amounts will be known or readily ascertainable by those skilled in the art. In many cases, said amounts are likely to be less than those presently administered by conventional delayed or sustained release dosage forms because of the high organ specificity of the dosage form of the present invention.
The drug is present in the dosage form of the invention in granular form. Suitably the granules are 0.25 to 4 mm, usually 0.25 to 2.5 mm, especially 0.4 to 1.5 mm and particularly about 0.6 mm, diameter.
The coating can be applied to the granules by any suitable known coating technique. In particular, conventional coating techniques such as spray or pan coating can be employed. (See, eg, "Film coatings on acrylic resin basis for dosage forms with controlled drug release" Pharma International 1/2 (1975) 3.) Preferabl}~, a 21 p468 6 the coating is applied from, aqueous suspension.
The granular coating material can be any suitable coating, eg. cellulose acetate phthalate, hydroxypropyl methyl cellulose phthalate, ethyl cellulose or polyvinyl acetate phthalate but the preferred coating material is an anionic polymer, especially one having the dissolution profile specified in EP-A-0097651, optionally in admixture with a neutral insoluble but permeable polymer. The l0 presently preferred anionic polymers are anionic carboxylic polymers, i.e. polymers in which the anionic groups are at least predominantly free carboxylic and/or esterified carboxylic groups. It is particularly preferred that the anion polymers should be acrylic polymers and the presently most preferred polymers are partly methyl esterified methacrylic acid polymers in which the ratio of free acid groups to ester groups is about 1:1 (i.e. Eudragit L), or especially, about 1:2 (i.e. Eudragit S). The neutral insoluble but permeable polymers preferably are acrylic ester polymers, especially methylmethacrylate ester copolymers with ethylacrylate., Suitably, the molecular ratio of anionic polymer to neutral polymer is in the range 5:1 to 1:5, especially 3:1 to 1:3, most preferably 1:1 to 1:3.
The thickness of coating required on the granules will depend upon the dissolution profile of the particular coating materials and possibly also upon the dissolution profile of the enteric coating on the capsule. However, it is well within the ability of the man of average skill in the art to determine by trial-and-error experimentation the optimum thickness of a particular coating required for a particular dosage form of the invention. When using an aqueous dispersion of a partly methyl esterified methacrylic acid polymer of the Eudragit S type admixed with a methylmethacrylate/ethylacrylate copolymer, the amount of coating material usually will be between 15 and 30% (dry weight based on the uncoated granule) with 20 to 25% being preferred.
The coating can, and usually will, contain plasticiser and possibly other coating additives such as colouring agents, gloss producers, talc and/or magnesium stearate as well known in the coating art. In particular, anionic carboxylic acrylic polymers usually contain 10 to 25% by weight of a plasticiser especially diethyl phthalate, although the presence of such a plasticiser may not be necessary when using an aqueous suspension for coating.
Usually, th.e capsule into which the coated granules are loaded will be a soft or, preferably, hard gelatin capsule although. other capsules which will dissolve in the small intestine can be used. The capsule is coated with an a 2~ p468 6 enteric coating which will protect it during passage through the stomach. Any conventional enteric coating material which is soluble in the small intestine can be used, eg. cellulose acetate phthalate, hydroxy propylmethyl cellulose phthalate or initially ethyl cellulose followed by polyvinyl acetate phthalate, but it is preferred to use an anionic polymer having an appropriate dissolution profile. The presently preferred polymers are anionic carboxylic polymers, i.e. polymers in which the anionic groups are at least predominantly free carboxylic and/or esterified carboxylic groups. It is particularly preferred that the polymers should be acrylic polymers and the presently most preferred polymers are partly methyl esterified methacrylic acid polymers in which the ratio of free acid groups to ester groups is about 1:1 (i.e.
Eudragit L).
The enteric coating can, and usually will contain plasticises and possibly other coating additives such as colouring agents, gloss producers, talc and/or magnesium stearate as well known in the coating art. I.~ particular, anionic carboxylic acrylic polymers usually contai:~ 10 to 25% by weight of a plasticises especially diethyl phthalate.
Conventional coating techniques such as spray or pan coating are employed to apply the enteric coating (See for ~,..., example D. Dreher "Film coatings on acrylic resin basis for dosage forms with controlled drug release" Pharma International 1/2 (1975) 3.) The following non-limiting Examples are provided to illustrate the dosage forms of the invention:-Granules of size in the range 0.5-2.1 mm were prepared l0 by dry compacting and subsequently sieving a tablet mass containing 5-ASA. The granules were then spray coated with an aqueous suspension to provide a 20% or 25% dry weight gain based on uncoated granule weight of a mixture of Eudragit 5100 and Eudragit NE 30 D (Rohm Pharma GmbH, Darmstadt, Germany) in the ratio of 3:7. Eudragit S100 is a copolymer of methacrylic acid and methylmethacrylate in the ratio of 1:2 in powder form and Eudragit NE 30 D is a 30% aqueous dispersion of a copolymer of ethylacrylate and methylmethacrylate in the ratio 2:1.
The resulting granules had the following formulations:-2~ o4s8 s MATERIAL 20% COATING 25% COATING
5-ASA 59.1 g 55.8 g Lactose 11.3 g 10.7 g Povidone (i.e. PVP) 1.3 g 1.2 g Explotab * (Na starch 2.7 g 2.5 g glycolate) Mg stearate 0.9 g 0.9 g Talc 9.2 g 10.6 g Eudragit 5100 4.6 g 5.4 g Eudragit NE 30 D 10.8 g 12.7 g Antifoam emulsion SE 0.1 g 0.1 g Total 100.0 g 100.0 g Each of the batches of coated granules were separately packed into size 00 hard gelatin capsules (LOK-CAP)*, Eli Lilly) in an amount of 400 mg granules per capsule. The capsules were then spray coated with 150 ml per capsule of a coating solution of the following formula:-Eudragit L powder 3 g Diethyl phthalate 0.75 ml Silicone fluid 200 cs 0.75 ml Acetone to 100 ml.
Seven healthy volunteers'were then each given blind on three separate occas~.ons a single dose consisting of (a) 8 * - Trade-marks ~;7 Y -1~- .21 0~:4 6 8 6 tablets of enteric coated 500 mg sulphasalazine tablets, (b) 8 of the enteric coated capsules containing the 20%
Eudragit coated 5-ASA granules, and (c) 8 of the enteric coated capsules containing the 25% Eudragit coated 5-ASA
granules. The serum levels of 5-ASA and N-acetyl-5-ASA at various times following administration were measured together with the total urinary excretion of 5-ASA and N-acetyl-5-ASA. The mean of the values recorded are set forth in the following Tables 1 to 3. In each case the values are given to three significant figures with 0 representing less than 2 ng/ml. The following abbreviations are used:-Tm~ - time for the maximum serum concentration in hours, median and interquartials ranges Cmax - maximum serum concentration attained in ng/ml .
AUC - area under the serum concentration time curve (50 h; ng.h/ml) Thalf - estimated biological half life of elimination KE - estimated first order in elimination rate constant i~
2~ 44ss s -18-Mean serum levels of 5-ASA (ng/ml) in 7 volunteers following administration of the three different drug formulations.
Time !h) 5-ASA 20% Sulp hasalazine 5-ASA
25%
FOR TREATMENT OF INTESTINAL DISORDERS
The present invention relates to the administration of drugs to the intestine and has particular, but not exclusive, application to the treatment of colonic disorders by administration to the ileum and/or colon of drugs such as 5-amino-salicylic acid (hereinafter referred to as 5-ASA).
Treatment of diseases of the intestine usually requires the delivery of a drug to the affected site. When the disease is essentially confined to a specific part of the intestine, such as the colon in ulcerative colitis or Crohn's colitis, it is desirable to target administration of the drug to that part in order to provide and control optimum local concentration of the drug. In this connection, some drugs such as 5-ASA are absorbed or inactivated in the small intestine.
The formulation of a drug in a conventional enteric coated capsule or tablet merely prevents release of the drug until the alkaline environment of the small intestine is reached. The problem of targeting the drug to the colon in an effective and viable manner was not solved until the proposal by the present inventors to coat solid oral dosage forms with a thick; coating of an anionic polymer of defined 2~ p468 6 pH dissolution profile (see EP-A-0097651).
Several "delayed release" forms of orally administrable drugs have been proposed. The delayed release may result from the physical properties of the formulation or from the chemical and physical properties of a derivative of the drug. It is known to provide capsules and tablets with a coating which will disintegrate to release the drug gradually when the capsule or tablet has reached the acid environment of the stomach or the alkaline environment of the small intestine. Similarly, it is known to provide capsules and tablets with a coating permeable to the drug contained and through which the drug is gradually released.
It was proposed in GB-A-1219026 (published January 1971) to embed individual particles of a drug in a slowly disintegrating or slowly dissolving resin matrix having a particular dissolution profile to provide an orally administrable formulation for selectively administering the drug to the large intestine. The resin is selected such that the drug remains substantially protected within the resin matrix while the particles travel through the stomach and small intestine of a patient and that the drug is substantially completely exposed at the time the particles reach the large intestine. In particular, the nature and amount of the resin is selected so that when a quantity of WO 92/14452 . . , . . . " PCT/GB92/00318 "....,, .
- ..2:1.04 8 6 the embedded drug is introduced into a Stoll-Gershberg disintegration apparatus, submerged in a simulated intestinal fluid (made in accordance with the U.S.
Pharmacopoeia, Volume XVII, 1965 at page 919 but modified by containing no pancreatin), and operated as described in the patent specification, 2% to 12% of the drug dissolves within an hour of the introduction of the formulation into the fluid and 18% to 88% of the drug dissolves within three hours of said introduction. It is specifically stated that the resin is selected so that the dissolution rate of the drug is not pH dependent but is time dependent. The preferred resin is a high-viscosity grade modified vinyl acetate resin (available under the Registered Trade Mark "Gelva" C3-V30) and other specified resins are carboxylated polyvinyl acetates, polyvinyl/maleic anhydride copolymers, poly(methacrylic acid), ethylene/maleic anhydride copolymers, ethyl cellulose, methylacrylic acid/methyl methacrylate copolymers, waxes and mixtures thereof including mixtures with shellac. Tablets of the embedded particles coated with a standard coating solution containing cellulose-acetate-phthalate are reported.
It will be appreciated that the carrier system disclosed in GB-A-1219026 relies upon the rate of disintegration or dissolution of the resin as the preparation passes through the gastro-intestinal tract.
The time dependency makes it impossible to limit a WO 92/14452 ~ , PCT/GB92/00318 administration of the drug to the colon because of large variations in the transit time in the gastro-intestinal tract, especially in the stomach, which occur between different patients and in the same patient from time to time. It would appear that the carrier system has not been satisfactory in practice because we are not aware of any relevant product presently available in the UK or elsewhere.
Anionic polymers have been known for many years to be of use in the preparation of coatings for capsules and to provide delayed or sustained release of an encapsulated drug. In particular, it has been known since at least 1974 to use for said coatings anionic copolymers of methacrylic acid and methacrylic acid methyl ester. Such a copolymer (available from Rohm Pharma GmbH, Darmstadt, Germany under the Registered Trade Mark "Eudragit" S) in which the ratio of free carboxyl groups to ester groups is approximately 1:2 and having a mean molecular weight of 135,000 is known to be insoluble in gastric juice and poorly soluble in intestinal juice while an analogous copolymer (available Rohm Pharma GmbH, Darmstadt, Germany under the Registered Trade Mark "Eudragit" L) differing only in so far as said ratio is approximately 1:1 also is insoluble in gastric juice but is readily soluble in intestinal juice. Prior to the invention of EP-A-0097651, said copolymers were usually employed to provide a coating of between 25 and 40 , ~~1- fl468 6 _5_ micrometers thick and the poorly soluble (in intestinal juice) copolymer usually is employed to reduce the dissolution (in intestinal juice) of the readily soluble copolymer. In general terms, except in connection with the invention of EP-A-0097651, anionic polymer coatings on oral dosage forms have been required to dissolve in aqueous medium at a pH below 7, usually between pH 5.5 and pH 7.
Eudragit S dissolves above pH 7 but, as noted above, usually is employed in admixture with Eudragit L. As far as we are aware, said mixtures invariably dissolve below pH
7.
Salicylazosulphapyridine (also known as sulphasalazine or salazopyrin and hereinafter referred to as SASP) consists of sulphapyridine linked to a salicylate group by a diazo bond and has been used for decades in the treatment of colitis, Crohn's disease, idiopathic proctitis and chronic arthritis. Orally administered SASP is only absorbed to a limited extent before reaching the colon where azo-reductases produced by colonic bacteria act to split SASP into sulphapyridine and 5-ASA. Studies by A.K.A. Khan et al (The Lancet, October 29 1977, p. 892) and others have shown the 5-ASA to be the pharmacologically active agent in the treatment of colonic disease with SASP.
Sulphasalazine appears merely to act as a chemical carrier to deliver 5-ASA to the colon. When administere~7 ~rai~~
without the azo-bond joining them, sulphapyridine and 5-ASA
a ~~ X46 8 6 -6_ are almost entirely absorbed from the small intestine before reaching the colon.
Several proposals have been made in recent years for the oral administration of 5-ASA avoiding using SASP in order to reduce the occurrence of side effects attributable to the sulphapyridine moiety. For example, in US-A-4190716 (published February 1980), it was proposed to covalently bond the 5-ASA to a nonabsorbable pharmacologically acceptable organic polymer backbone comprising a plurality of aromatic rings by azo bonds bridging aromatic carbon atoms and the 5-position carbon of 5-ASA.
In GB-A-2021409 (published December 1979), it was proposed that 5-ASA should be administered concurrently or concomitantly with certain disodium cromoglycate-like compounds. Reference is made to formulating 5-ASA in sustained or controlled release form by coating some or all 5-ASA particles or granules thereof with a slowly soluble or digestible or semi- permeable layer of material such as beeswax, Carnauba wax, stearic or palmitic acids or cetyl alcohol. Reference also is made to coating tablets of the coated or uncoated 5-ASA with a continuous film of a material such as shellac or cellulose acetate phthalate which is resistant and impermeable to gastric secretions but susceptible to intestinal secretions. None of the coating materials specified or indicated in the 2'l p488 6 specification are such as to prevent release of 5-ASA until the colon.
WO-A-81/02671 (published October 1981) proposed formulating 5-ASA in a sustained release tablet or enterosoluble tablet form and specifies ethyl cellulose as the preferred coating material. No coating materials other than cellulose derivatives are mentioned and it is granules, as distinct from tablets or other solid oral dosage forms, which are described as being coated. The coating is intended to provide sustained release of 5-ASA
throughout the small and large intestine.
EP-A-0040590 (published November 1981) proposes coating a core of 5-ASA with a coating material comprising at least, (a) 10 to 85o by weight of an anionic carboxylic polymer soluble only above pH 5.5 and (b) 15 to 90% by weight of a water-soluble, quaternary ammonium substituted acrylic polymer. It is stated that the coating normally will be 3 to 60, preferably 10 to 30, micrometers thick and that partly methyl esterified methacrylic acid polymers are suitable anionic carboxylic polymers for use as component (a). In the Examples, Eudragit L and a mixture of Eudragit L and Eudragit S constitute the component (a) and in all cases the coatings dissolved below pH 7. The coated bodies of the EP-A-0040590 are subsequently included in dosage units which normally contain at least 10 coated bodies.
a _8_ 2~ 046s s The rationale of the coating system is stated to be that the change of pH from acid to neutral at the pylorus triggers a change in the physical condition of the coating so that 5-ASA is subsequently released after a predetermined time lag by which time the formulation should have reached the colon. Although time of passage through the small intestine is relatively constant, it still varies from 2 to 5 hours and hence the carrier system does not provide for reliable release of 5-ASA specifically in the colon.
EP-A-0097651 (published February 1983 as WO-A-8300435) disclosed that 5-ASA reliably can be administered specifically to the large intestine, especially the colon, by simply coating a solid oral dosage form with a 60 to 150 micrometers thick layer of an anionic polymer which is insoluble in gastric juice and in intestinal juice below pH
7 but soluble in colonic intestinal juice, whereby the oral dosage form remains intact until it reaches the colon.
This carrier system differs from those previously disclosed in relation to 5-ASA in that dissolution or disintegration does not occur until entry of the coated dosage form into the colon. In particular, there is substantially no leaching out of the 5-ASA downstream of the colon in the normal patient. The carrier system is not limited to 5-ASA
but can be used for other drugs, such as prednisolone methasulphobenzoate, which require to be targeted to the ",..., _ 21 p468 6 colon.
Although the 5-ASA formulation of EP-A-0097651 has found widespread and increasing use in the treatment of ulcerative colitis or Crohn's colitis, there are occasions upon which it would be desirable to avoid the release of a large bolus of 5-ASA or other drug in the colon and to deliver the drug in smaller quantities. instead to give more of a plateau release than the rapid peak absorption caused by bolus releases and to reduce the risk of local irritation. Further, it is desirable to provide a more flexible release system which would permit targeted release in the small intestine instead of in the colon.
Accordingly, we have investigated the possibility of alternative formulations for targeting drugs to the intestine. As a result of those investigations, we have found that the drug can successfully be targeted by replacing the coated oral dosage form of EP-A-0097651 with individually coated granules within an enteric coated capsule.
In its broadest aspect, the present invention provides an orally administrable pharmaceutical dosage form for selectively administering a drug to the intestine comprising a plurality of granules of the drug contained in . a capsule, characterized in that said granules and said capsule are coated with the same or different coating n 2~ p4fi8 6 . . _ -1~-material which dissolves in the intestine.
According to a preferred embodiment, the present invention provides an orally administrable pharmaceutical dosage form for selectively administering a drug to the large intestine comprising a plurality of granules of the drug contained~in an enterically coated capsule which releases the granules in the small intestine, characterized in that said granules are coated with a coating which remains substantially intact until the coated granules reach at least the ileum and, preferably, thereafter provides a sustained release of the drug in the colon.
According to an especially preferred embodiment of the present invention, there is provided an orally administrable pharmaceutical dosage form for selectively administering a drug to the colon comprising a plurality of granules of the drug contained in an enterically coated capsule which releases the granules in the small intestine, characterized in that said granules are coated with a coating material comprising an anionic polymei which is insoluble in gastric juice and in intestinal juice below pH
7 but is soluble in colonic intestinal juice whereby the coating on the released coated granules remains substantially intact until the granules reach at least the ileum and, preferably, thereafter provides a sustained release of the drug in the colon.
Although the invention has particular application to 5-ASA, it can be used to target any desired drug, especially a topically active drug, to the intestine. In particular, it has application to the administration of topically active steroids such as prednisolone metasulphobenzoate to the ileum and/or colon. Other drugs which can be administered by the invention include bismuth salts or complexes, for example bismuth-carbomer complexes.
The relevant drug will be present in the dosage form of the invention in suitable unit dose amounts. Said amounts will be known or readily ascertainable by those skilled in the art. In many cases, said amounts are likely to be less than those presently administered by conventional delayed or sustained release dosage forms because of the high organ specificity of the dosage form of the present invention.
The drug is present in the dosage form of the invention in granular form. Suitably the granules are 0.25 to 4 mm, usually 0.25 to 2.5 mm, especially 0.4 to 1.5 mm and particularly about 0.6 mm, diameter.
The coating can be applied to the granules by any suitable known coating technique. In particular, conventional coating techniques such as spray or pan coating can be employed. (See, eg, "Film coatings on acrylic resin basis for dosage forms with controlled drug release" Pharma International 1/2 (1975) 3.) Preferabl}~, a 21 p468 6 the coating is applied from, aqueous suspension.
The granular coating material can be any suitable coating, eg. cellulose acetate phthalate, hydroxypropyl methyl cellulose phthalate, ethyl cellulose or polyvinyl acetate phthalate but the preferred coating material is an anionic polymer, especially one having the dissolution profile specified in EP-A-0097651, optionally in admixture with a neutral insoluble but permeable polymer. The l0 presently preferred anionic polymers are anionic carboxylic polymers, i.e. polymers in which the anionic groups are at least predominantly free carboxylic and/or esterified carboxylic groups. It is particularly preferred that the anion polymers should be acrylic polymers and the presently most preferred polymers are partly methyl esterified methacrylic acid polymers in which the ratio of free acid groups to ester groups is about 1:1 (i.e. Eudragit L), or especially, about 1:2 (i.e. Eudragit S). The neutral insoluble but permeable polymers preferably are acrylic ester polymers, especially methylmethacrylate ester copolymers with ethylacrylate., Suitably, the molecular ratio of anionic polymer to neutral polymer is in the range 5:1 to 1:5, especially 3:1 to 1:3, most preferably 1:1 to 1:3.
The thickness of coating required on the granules will depend upon the dissolution profile of the particular coating materials and possibly also upon the dissolution profile of the enteric coating on the capsule. However, it is well within the ability of the man of average skill in the art to determine by trial-and-error experimentation the optimum thickness of a particular coating required for a particular dosage form of the invention. When using an aqueous dispersion of a partly methyl esterified methacrylic acid polymer of the Eudragit S type admixed with a methylmethacrylate/ethylacrylate copolymer, the amount of coating material usually will be between 15 and 30% (dry weight based on the uncoated granule) with 20 to 25% being preferred.
The coating can, and usually will, contain plasticiser and possibly other coating additives such as colouring agents, gloss producers, talc and/or magnesium stearate as well known in the coating art. In particular, anionic carboxylic acrylic polymers usually contain 10 to 25% by weight of a plasticiser especially diethyl phthalate, although the presence of such a plasticiser may not be necessary when using an aqueous suspension for coating.
Usually, th.e capsule into which the coated granules are loaded will be a soft or, preferably, hard gelatin capsule although. other capsules which will dissolve in the small intestine can be used. The capsule is coated with an a 2~ p468 6 enteric coating which will protect it during passage through the stomach. Any conventional enteric coating material which is soluble in the small intestine can be used, eg. cellulose acetate phthalate, hydroxy propylmethyl cellulose phthalate or initially ethyl cellulose followed by polyvinyl acetate phthalate, but it is preferred to use an anionic polymer having an appropriate dissolution profile. The presently preferred polymers are anionic carboxylic polymers, i.e. polymers in which the anionic groups are at least predominantly free carboxylic and/or esterified carboxylic groups. It is particularly preferred that the polymers should be acrylic polymers and the presently most preferred polymers are partly methyl esterified methacrylic acid polymers in which the ratio of free acid groups to ester groups is about 1:1 (i.e.
Eudragit L).
The enteric coating can, and usually will contain plasticises and possibly other coating additives such as colouring agents, gloss producers, talc and/or magnesium stearate as well known in the coating art. I.~ particular, anionic carboxylic acrylic polymers usually contai:~ 10 to 25% by weight of a plasticises especially diethyl phthalate.
Conventional coating techniques such as spray or pan coating are employed to apply the enteric coating (See for ~,..., example D. Dreher "Film coatings on acrylic resin basis for dosage forms with controlled drug release" Pharma International 1/2 (1975) 3.) The following non-limiting Examples are provided to illustrate the dosage forms of the invention:-Granules of size in the range 0.5-2.1 mm were prepared l0 by dry compacting and subsequently sieving a tablet mass containing 5-ASA. The granules were then spray coated with an aqueous suspension to provide a 20% or 25% dry weight gain based on uncoated granule weight of a mixture of Eudragit 5100 and Eudragit NE 30 D (Rohm Pharma GmbH, Darmstadt, Germany) in the ratio of 3:7. Eudragit S100 is a copolymer of methacrylic acid and methylmethacrylate in the ratio of 1:2 in powder form and Eudragit NE 30 D is a 30% aqueous dispersion of a copolymer of ethylacrylate and methylmethacrylate in the ratio 2:1.
The resulting granules had the following formulations:-2~ o4s8 s MATERIAL 20% COATING 25% COATING
5-ASA 59.1 g 55.8 g Lactose 11.3 g 10.7 g Povidone (i.e. PVP) 1.3 g 1.2 g Explotab * (Na starch 2.7 g 2.5 g glycolate) Mg stearate 0.9 g 0.9 g Talc 9.2 g 10.6 g Eudragit 5100 4.6 g 5.4 g Eudragit NE 30 D 10.8 g 12.7 g Antifoam emulsion SE 0.1 g 0.1 g Total 100.0 g 100.0 g Each of the batches of coated granules were separately packed into size 00 hard gelatin capsules (LOK-CAP)*, Eli Lilly) in an amount of 400 mg granules per capsule. The capsules were then spray coated with 150 ml per capsule of a coating solution of the following formula:-Eudragit L powder 3 g Diethyl phthalate 0.75 ml Silicone fluid 200 cs 0.75 ml Acetone to 100 ml.
Seven healthy volunteers'were then each given blind on three separate occas~.ons a single dose consisting of (a) 8 * - Trade-marks ~;7 Y -1~- .21 0~:4 6 8 6 tablets of enteric coated 500 mg sulphasalazine tablets, (b) 8 of the enteric coated capsules containing the 20%
Eudragit coated 5-ASA granules, and (c) 8 of the enteric coated capsules containing the 25% Eudragit coated 5-ASA
granules. The serum levels of 5-ASA and N-acetyl-5-ASA at various times following administration were measured together with the total urinary excretion of 5-ASA and N-acetyl-5-ASA. The mean of the values recorded are set forth in the following Tables 1 to 3. In each case the values are given to three significant figures with 0 representing less than 2 ng/ml. The following abbreviations are used:-Tm~ - time for the maximum serum concentration in hours, median and interquartials ranges Cmax - maximum serum concentration attained in ng/ml .
AUC - area under the serum concentration time curve (50 h; ng.h/ml) Thalf - estimated biological half life of elimination KE - estimated first order in elimination rate constant i~
2~ 44ss s -18-Mean serum levels of 5-ASA (ng/ml) in 7 volunteers following administration of the three different drug formulations.
Time !h) 5-ASA 20% Sulp hasalazine 5-ASA
25%
3.5 102 + 88 0 + 0 70 + 40 5 227 + 142 7 + 4 155 + 65 6.5 153 + 101 30 + 19 54 + 22 8 193 + 108 30 + 15 73 37 9.5 143 + 104 49 + 19 37 15 12 17 + 7 61 + 29 17 9 15 38 + 23 99 + 31 22 + 15 26 56 + 28 43 + 23 4 + 3 36 19 + 10 12 + 9 10 10 Tmax 6.5(3.1-13.6) 15(6.5-15) 5 (3.8-6.9) Cmax 400 + 142 102 32 215 54 AUC 2480 + 450 1610 664 1080 299 Thalf 7.2 + 3.0 19.4 12.9 1.7 0.6 KE 0.2 0.1 0.1 0.04 0.7 0.3 Mean serum levels of N-Ac-5-ASA (ng/ml) in 7 volunteers following administration of the three different drug formulations.
Time lhl 5-ASA 20% Sulp hasalazine 5-ASA
25%
3.5 383 + 267 18 + 17 258 + 113 5 756 + 388 97 + 52 473 + 174 6.5 714 + 280 186 + 84 410 + 93 8 650 + 228 343 + 134 453 + 77 9.5 545 + 205 391 117 436 69 12 417 + 119 556 + 88 440 + 151 15 425 + 184 763 + 151 355 + 86 26 590 + 124 505 + 130 182. + 40 36 389 + 140 285 + 117 169 + 72 50 188 + 92 191 + 133 125 + 92 Tm~ 26(6.1-26) 15(13.3-17.8) 8 (5-9.5) 1420 + 296 841 + 153 822 + 112 AUC 21300 18400 +3820 11800 +2090 +2270 Th~f 10.8 + 2.4 60.1 + 50.1 12.8 + 4.5 KE 0.1 + 0.02 0.1 + 0.02 0.1 + 0.01 n Mean urinary excretion of 5-ASA and N-Ac-5-ASA (ng/ml) in 7 volunteers following administration of the three different drug formulations.
5-ASA 20% Sulphasalazine 5-ASA 25%
5-ASA 5.35 + 2.59 0 + 0 1.40 + 0.35 N-AC-5-ASA 194 + 24 170 + 35 129 + 29 As can be-seen from the tables, the mean serum concentrations of 5-ASA were lower than those of its acetylated metabolite following oral ingestion of each of the three preparations. Peak concentrations of serum 5-ASA
and N-acetyl-5-ASA occurred earlier with both 5-ASA
capsules compared with sulphasalazine. However, following administration of the capsule containing 20% Eudragit coated 5-ASA there was a second rise in both serum 5-ASA
and N-acetyl-5-ASA at 15 h, with levels thereafter similar to those after sulphasalazine.
These results suggest that more 5-ASA is available for earlier absorption after ingestion of the 5-ASA capsules than after sulphasalazine. The early peaks after both capsules correspond to drug absorbed in the small bowel following dissolution of the capsule coated with Eudragit-L. Other granules reach the terminal ileum and proximal l.~ 't~.. ~ (.,.' 4... ,.
-21- ~2~ o~ss s colon where, at a pH above 7, further drug release would be expected. This accounts for the second rises of serum 5-ASA and N-acetyl-5-ASA seen 15 hours after ingestion of the capsule containing 20% Eudragit coated 5-ASA.
Release of free 5-ASA in the proximal small bowel, or substantial release of the drug in one region of the ileal or ileo-caecal area, can lead to high peak serum levels of 5-ASA and its metabolites, leaving less drug available for topical action in the colon. The coated granules/coated capsules of this invention deliver 5-ASA to the distal small bowel, limit sudden release of free compound, and make the drug available for absorption over a longer period as with sulphasalazine.
example 2 The granule coating procedure of Example 1 was repeated using 12%, 16%, 20%, 22% and 25% of the coating mixture. The dissolution of the coated granules was examined by a standard flow-through cell dissolution system which automatically changed the pH at pre-determined time intervals. The coated granules were exposed to pH 1.2 for 2 h, then pH 6.4 for 1 h, and finally pH 7.2 for 1 h. 5-ASA was measured spectrophotometrically and the results are shown in Fig. 1.
a ~~,,~ ~~68 6 As can be seen, the pH influenced the drug release from granules coated with at least 16% dry lacquer substance.
With 20% of dry lacquer substance, the amount of 5-ASA
release after 2 h at pH 1.2 was 7.8%, compared with 18.5%
at pH 6.4 for'1 h, and 77.8% after 1 h at pH 7.2 (accumulated percentages); with 25% of dry lacquer substance the respective percentage 5-ASA release was 3.6%, 10% and 48%.
Time lhl 5-ASA 20% Sulp hasalazine 5-ASA
25%
3.5 383 + 267 18 + 17 258 + 113 5 756 + 388 97 + 52 473 + 174 6.5 714 + 280 186 + 84 410 + 93 8 650 + 228 343 + 134 453 + 77 9.5 545 + 205 391 117 436 69 12 417 + 119 556 + 88 440 + 151 15 425 + 184 763 + 151 355 + 86 26 590 + 124 505 + 130 182. + 40 36 389 + 140 285 + 117 169 + 72 50 188 + 92 191 + 133 125 + 92 Tm~ 26(6.1-26) 15(13.3-17.8) 8 (5-9.5) 1420 + 296 841 + 153 822 + 112 AUC 21300 18400 +3820 11800 +2090 +2270 Th~f 10.8 + 2.4 60.1 + 50.1 12.8 + 4.5 KE 0.1 + 0.02 0.1 + 0.02 0.1 + 0.01 n Mean urinary excretion of 5-ASA and N-Ac-5-ASA (ng/ml) in 7 volunteers following administration of the three different drug formulations.
5-ASA 20% Sulphasalazine 5-ASA 25%
5-ASA 5.35 + 2.59 0 + 0 1.40 + 0.35 N-AC-5-ASA 194 + 24 170 + 35 129 + 29 As can be-seen from the tables, the mean serum concentrations of 5-ASA were lower than those of its acetylated metabolite following oral ingestion of each of the three preparations. Peak concentrations of serum 5-ASA
and N-acetyl-5-ASA occurred earlier with both 5-ASA
capsules compared with sulphasalazine. However, following administration of the capsule containing 20% Eudragit coated 5-ASA there was a second rise in both serum 5-ASA
and N-acetyl-5-ASA at 15 h, with levels thereafter similar to those after sulphasalazine.
These results suggest that more 5-ASA is available for earlier absorption after ingestion of the 5-ASA capsules than after sulphasalazine. The early peaks after both capsules correspond to drug absorbed in the small bowel following dissolution of the capsule coated with Eudragit-L. Other granules reach the terminal ileum and proximal l.~ 't~.. ~ (.,.' 4... ,.
-21- ~2~ o~ss s colon where, at a pH above 7, further drug release would be expected. This accounts for the second rises of serum 5-ASA and N-acetyl-5-ASA seen 15 hours after ingestion of the capsule containing 20% Eudragit coated 5-ASA.
Release of free 5-ASA in the proximal small bowel, or substantial release of the drug in one region of the ileal or ileo-caecal area, can lead to high peak serum levels of 5-ASA and its metabolites, leaving less drug available for topical action in the colon. The coated granules/coated capsules of this invention deliver 5-ASA to the distal small bowel, limit sudden release of free compound, and make the drug available for absorption over a longer period as with sulphasalazine.
example 2 The granule coating procedure of Example 1 was repeated using 12%, 16%, 20%, 22% and 25% of the coating mixture. The dissolution of the coated granules was examined by a standard flow-through cell dissolution system which automatically changed the pH at pre-determined time intervals. The coated granules were exposed to pH 1.2 for 2 h, then pH 6.4 for 1 h, and finally pH 7.2 for 1 h. 5-ASA was measured spectrophotometrically and the results are shown in Fig. 1.
a ~~,,~ ~~68 6 As can be seen, the pH influenced the drug release from granules coated with at least 16% dry lacquer substance.
With 20% of dry lacquer substance, the amount of 5-ASA
release after 2 h at pH 1.2 was 7.8%, compared with 18.5%
at pH 6.4 for'1 h, and 77.8% after 1 h at pH 7.2 (accumulated percentages); with 25% of dry lacquer substance the respective percentage 5-ASA release was 3.6%, 10% and 48%.
Claims (11)
1. An orally administrable pharmaceutical dosage form for selectively administering a drug to the intestine comprising a plurality of granules of the drug contained in a capsule, wherein said granules are individually coated and said capsule are coated with the same or different coating material which dissolves in the intestine.
2. A dosage form as claimed in claim 1 comprising a plurality of granules of the drug contained in an enterically coated capsule which releases the granules in the small intestine, characterized in that said granules are coated with a coating which remains substantially intact until the coated granules reach at least the ileum.
3. A dosage form as claimed in claim 2, wherein said coating provides a sustained release of the drug in the colon.
4. A dosage form as claimed in claim 2, wherein said granule coating comprises an anionic polymer which is insoluble in gastric juice and in intestinal juice below pH 7 but is soluble in colonic intestinal juice whereby coating on the released coated granules remains substantially intact until the granules reach at least the ileum.
12. A dosage form as claimed in Claim 11, wherein the capsule coating is a partly methyl esterified methacrylic acid polymer.
13. A dosage form as claimed in Claim 12, wherein the capsule coating is a partly methyl esterified methacrylic acid polymer having a ratio of free acid groups to ester groups of about 1:1
12. A dosage form as claimed in Claim 11, wherein the capsule coating is a partly methyl esterified methacrylic acid polymer.
13. A dosage form as claimed in Claim 12, wherein the capsule coating is a partly methyl esterified methacrylic acid polymer having a ratio of free acid groups to ester groups of about 1:1
5. A dosage form as claimed in Claim 4, wherein said coating provides a sustained release of the drug in the colon.
6. A dosage form as claimed in Claim 1, wherein said drug is 5-aminosalicylic acid or a pharmaceutically acceptable salt or ester thereof.
7. A dosage form as claimed in Claim 1, wherein the drug is a topically active steroid or a bismuth salt or complex.
8. A dosage form as claimed in Claim 4, wherein the anionic polymer is a partly methyl esterified methacrylic acid polymer.
9. A dosage form as claimed in Claim 8, wherein the partly methyl esterified methacrylic acid polymer has a ratio of free acid groups to ester groups of about 1:2.
l0. A dosage form as claimed in Claim 1, wherein the capsule is a hard gelatin capsule.
11. A dosage form as claimed in Claim 1, wherein the capsule is coated with an anionic carboxylic acrylic polymer.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9103795A GB2253346A (en) | 1991-02-22 | 1991-02-22 | Delayed release oral dosage forms for treatment of intestinal disorders |
| GB9103795.2 | 1991-02-22 | ||
| PCT/GB1992/000318 WO1992014452A1 (en) | 1991-02-22 | 1992-02-21 | Delayed release oral dosage forms for treatment of intestinal disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2104686A1 CA2104686A1 (en) | 1992-08-23 |
| CA2104686C true CA2104686C (en) | 2000-05-02 |
Family
ID=10690451
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002104686A Expired - Lifetime CA2104686C (en) | 1991-02-22 | 1992-02-21 | Delayed release oral dosage forms for treatment of intestinal disorders |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US5401512A (en) |
| EP (1) | EP0572486B1 (en) |
| JP (1) | JP2958116B2 (en) |
| KR (1) | KR100220322B1 (en) |
| AT (1) | ATE129893T1 (en) |
| AU (1) | AU652032B2 (en) |
| CA (1) | CA2104686C (en) |
| CZ (1) | CZ281792B6 (en) |
| DE (1) | DE69205971T2 (en) |
| DK (1) | DK0572486T3 (en) |
| ES (1) | ES2079183T3 (en) |
| FI (1) | FI105255B (en) |
| GB (1) | GB2253346A (en) |
| GE (1) | GEP19971086B (en) |
| GR (1) | GR3018455T3 (en) |
| HU (1) | HU219449B (en) |
| IE (1) | IE74225B1 (en) |
| IL (1) | IL101036A (en) |
| IN (1) | IN179089B (en) |
| NO (1) | NO307405B1 (en) |
| NZ (1) | NZ241687A (en) |
| WO (1) | WO1992014452A1 (en) |
| YU (1) | YU17892A (en) |
Families Citing this family (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0542299B1 (en) * | 1991-11-15 | 1999-08-04 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | Ester linkage containing polymers for use in pharmaceutical preparations |
| US5322697A (en) * | 1992-05-28 | 1994-06-21 | Meyer James H | Composition and method for inducing satiety |
| US6204243B1 (en) | 1993-09-01 | 2001-03-20 | Novatis Ag | Pharmaceutical preparations for the targeted treatment of crohn's disease and ulcerative colitis |
| GB2292079B (en) * | 1994-08-12 | 1998-07-15 | Flexpharm Ltd | Coated prednisolone preparation for the treatment of inflamatory bowel disease |
| US6166024A (en) * | 1995-03-30 | 2000-12-26 | Mayo Foundation For Medical Education And Research | Use of topical azathioprine and thioguanine to treat colorectal adenomas |
| US20040018236A1 (en) * | 1995-05-08 | 2004-01-29 | Robert Gurny | Nanoparticles for oral administration of pharmaceutical agents of low solubility |
| GB2300807B (en) * | 1995-05-15 | 1999-08-18 | Tillotts Pharma Ag | Oral dosage forms of omega-3 polynunsaturated acids for the treatment of inflammatory bowel disease |
| AUPN327695A0 (en) * | 1995-05-30 | 1995-06-22 | Chemeq Pty. Limited | Chemotherapeutic compositions |
| US6004581A (en) * | 1995-12-21 | 1999-12-21 | Farmaceutisk Laboratorium Ferring A/S | Modified release oral pharmaceutical composition and method for the treatment of bowel diseases |
| US5889028A (en) * | 1996-02-09 | 1999-03-30 | Mayo Foundation For Medical Education And Research | Colonic delivery of nicotine to treat inflammatory bowel disease |
| US5846983A (en) * | 1996-02-09 | 1998-12-08 | Mayo Foundation For Medical Education And Research | Colonic delivery of nicotine to treat inflammatory bowel disease |
| US5908912A (en) * | 1996-09-06 | 1999-06-01 | Ppg Industries Ohio, Inc. | Electrodepositable coating composition containing bismuth and amino acid materials and electrodeposition method |
| GB9620709D0 (en) * | 1996-10-04 | 1996-11-20 | Danbiosyst Uk | Colonic delivery of weak acid drugs |
| US6544523B1 (en) | 1996-11-13 | 2003-04-08 | Chiron Corporation | Mutant forms of Fas ligand and uses thereof |
| DE19732903A1 (en) | 1997-07-30 | 1999-02-04 | Falk Pharma Gmbh | Pellet formulation for the treatment of the intestinal tract |
| US20090149479A1 (en) * | 1998-11-02 | 2009-06-11 | Elan Pharma International Limited | Dosing regimen |
| US20070122481A1 (en) * | 1998-11-02 | 2007-05-31 | Elan Corporation Plc | Modified Release Compositions Comprising a Fluorocytidine Derivative for the Treatment of Cancer |
| US20090297597A1 (en) * | 1998-11-02 | 2009-12-03 | Gary Liversidge | Modified Release Ticlopidine Compositions |
| US20060240105A1 (en) * | 1998-11-02 | 2006-10-26 | Elan Corporation, Plc | Multiparticulate modified release composition |
| DK1126826T6 (en) * | 1998-11-02 | 2019-06-24 | Alkermes Pharma Ireland Ltd | Multiparticulate modified release of methylphenidate |
| MXPA01007463A (en) | 1999-01-29 | 2002-06-04 | Losan Pharma Gmbh | Pharmaceutical compositions. |
| ITMI991316A1 (en) * | 1999-06-14 | 2000-12-14 | Cip Ninety Two 92 S A | ORAL PHARMACEUTICAL COMPOSITIONS WITH MODIFIED RELEASE OF MESALAZINE |
| US20040115134A1 (en) * | 1999-06-22 | 2004-06-17 | Elan Pharma International Ltd. | Novel nifedipine compositions |
| NZ529928A (en) | 1999-10-29 | 2005-10-28 | Euro Celtique Sa | Controlled release hydrocodone formulations |
| US10179130B2 (en) | 1999-10-29 | 2019-01-15 | Purdue Pharma L.P. | Controlled release hydrocodone formulations |
| US6667042B2 (en) | 2000-02-24 | 2003-12-23 | Advancis Pharmaceutical Corp. | Fluroquinilone antibiotic product, use and formulation thereof |
| US6669948B2 (en) | 2000-02-24 | 2003-12-30 | Advancis Pharmaceutical Corp. | Antibiotic product, use and formulation thereof |
| US6610328B2 (en) | 2000-02-24 | 2003-08-26 | Advancis Pharmaceutical Corp. | Amoxicillin-clarithromycin antibiotic composition |
| US6991807B2 (en) * | 2000-02-24 | 2006-01-31 | Advancis Pharmaceutical, Corp. | Antibiotic composition |
| US6632453B2 (en) | 2000-02-24 | 2003-10-14 | Advancis Pharmaceutical Corp. | Ciprofoxacin-metronidazole antibiotic composition |
| US6663890B2 (en) | 2000-02-24 | 2003-12-16 | Advancis Pharmaceutical Corp. | Metronidazole antibiotic product, use and formulation thereof |
| AU2001239841B2 (en) | 2000-02-24 | 2006-04-27 | Shionogi, Inc. | Antibiotic and antifungal compositions |
| US6565882B2 (en) | 2000-02-24 | 2003-05-20 | Advancis Pharmaceutical Corp | Antibiotic composition with inhibitor |
| US6638532B2 (en) | 2000-02-24 | 2003-10-28 | Advancis Pharmaceutical Corp. | Tetracycline—doxycycline antibiotic composition |
| US6663891B2 (en) | 2000-02-24 | 2003-12-16 | Advancis Pharmaceutical Corp. | Erythromyacin antibiotic product, use and formulation thereof |
| US6730320B2 (en) | 2000-02-24 | 2004-05-04 | Advancis Pharmaceutical Corp. | Tetracycline antibiotic product, use and formulation thereof |
| US6627222B2 (en) | 2000-02-24 | 2003-09-30 | Advancis Pharmaceutical Corp. | Amoxicillin-dicloxacillin antibiotic composition |
| US6667057B2 (en) | 2000-02-24 | 2003-12-23 | Advancis Pharmaceutical Corp. | Levofloxacin antibiotic product, use and formulation thereof |
| US6544555B2 (en) * | 2000-02-24 | 2003-04-08 | Advancis Pharmaceutical Corp. | Antibiotic product, use and formulation thereof |
| US7025989B2 (en) * | 2000-02-24 | 2006-04-11 | Advancis Pharmaceutical Corp. | Multiple-delayed released antibiotic product, use and formulation thereof |
| US6623758B2 (en) | 2000-02-24 | 2003-09-23 | Advancis Pharmaceutical Corp. | Cephalosporin-metronidazole antibiotic composition |
| IT1318376B1 (en) * | 2000-03-07 | 2003-08-25 | Pharmatec Internat S R L | ORAL SOLID FORMS WITH CONTROLLED RELEASE CONTAINING MESALAZINE AS AN ACTIVE PRINCIPLE. |
| US6541014B2 (en) * | 2000-10-13 | 2003-04-01 | Advancis Pharmaceutical Corp. | Antiviral product, use and formulation thereof |
| US7074417B2 (en) * | 2000-10-13 | 2006-07-11 | Advancis Pharmaceutical Corporation | Multiple-delayed release anti-viral product, use and formulation thereof |
| US20020068078A1 (en) * | 2000-10-13 | 2002-06-06 | Rudnic Edward M. | Antifungal product, use and formulation thereof |
| US7157095B2 (en) * | 2000-10-13 | 2007-01-02 | Advancis Pharmaceutical Corporation | Multiple-delayed release antifungal product, use and formulation thereof |
| US7105174B2 (en) * | 2000-10-13 | 2006-09-12 | Advancis Pharmaceutical Corporation | Multiple-delayed release anti-neoplastic product, use and formulation thereof |
| KR101045144B1 (en) | 2000-10-30 | 2011-06-30 | 유로-셀티크 소시에떼 아노뉨 | Controlled release hydrocodone formulations |
| CA2359812C (en) * | 2000-11-20 | 2004-02-10 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures |
| US6887492B2 (en) | 2000-12-14 | 2005-05-03 | Leiner Health Services Corp. | Magnesium plus interactive agent delivery |
| US6824559B2 (en) * | 2000-12-22 | 2004-11-30 | Advanced Cardiovascular Systems, Inc. | Ethylene-carboxyl copolymers as drug delivery matrices |
| US20020197314A1 (en) * | 2001-02-23 | 2002-12-26 | Rudnic Edward M. | Anti-fungal composition |
| FR2830446B1 (en) * | 2001-10-09 | 2004-02-06 | Univ Pasteur | PHARMACEUTICAL COMPOSITION FOR RELEASING AN ACTIVE SUBSTANCE AT THE COLON |
| AR036797A1 (en) | 2001-10-15 | 2004-10-06 | Ferring Bv | A METHOD TO PREPARE A PHARMACEUTICAL COMPOSITION THAT INCLUDES 5-AMINOSALICILIC ACID TO USE IN THE TREATMENT OF ULCEROSE COLITIS AND CROHN DISEASES |
| US20080220074A1 (en) * | 2002-10-04 | 2008-09-11 | Elan Corporation Plc | Gamma radiation sterilized nanoparticulate docetaxel compositions and methods of making same |
| US20040114368A1 (en) * | 2002-12-13 | 2004-06-17 | Shyu Shing Jy | Light device having rotatable or movable view |
| JP2007523664A (en) | 2003-04-23 | 2007-08-23 | フェリング ベスローテン フェンノートシャップ | Sachet for pharmaceutical composition |
| CA2533178C (en) * | 2003-07-21 | 2014-03-11 | Advancis Pharmaceutical Corporation | Antibiotic product, use and formulation thereof |
| WO2005009364A2 (en) * | 2003-07-21 | 2005-02-03 | Advancis Pharmaceutical Corporation | Antibiotic product, use and formulation thereof |
| CA2533292C (en) * | 2003-07-21 | 2013-12-31 | Advancis Pharmaceutical Corporation | Antibiotic product, use and formulation thereof |
| WO2005016311A1 (en) * | 2003-08-11 | 2005-02-24 | Advancis Pharmaceutical Corporation | Robust pellet |
| AU2004264356B2 (en) * | 2003-08-12 | 2011-01-27 | Shionogi, Inc. | Antibiotic product, use and formulation thereof |
| JP5686494B2 (en) * | 2003-08-29 | 2015-03-18 | シオノギ インコーポレイテッド | Antibiotic preparations, their use and preparation |
| EP1663169A4 (en) * | 2003-09-15 | 2010-11-24 | Middlebrook Pharmaceuticals In | Antibiotic product, use and formulation thereof |
| US7387793B2 (en) | 2003-11-14 | 2008-06-17 | Eurand, Inc. | Modified release dosage forms of skeletal muscle relaxants |
| AU2004308419B2 (en) * | 2003-12-24 | 2011-06-02 | Victory Pharma, Inc. | Enhanced absorption of modified release dosage forms |
| GB0403247D0 (en) | 2004-02-13 | 2004-03-17 | Tillotts Pharma Ag | A pharmaceutical composition |
| CN104292321A (en) | 2004-03-29 | 2015-01-21 | 株式会社嘉尔药物 | Novel modified galectin 9 protein and use thereof |
| EP1768668A2 (en) | 2004-06-16 | 2007-04-04 | Tap Pharmaceutical Products, Inc. | Multiple ppi dosage form |
| JP2008505124A (en) * | 2004-07-02 | 2008-02-21 | アドバンシス ファーマスーティカル コーポレイション | Pulse delivery tablets |
| EP2801354B1 (en) | 2004-10-08 | 2017-02-08 | Forward Pharma A/S | Controlled release pharmaceutical compositions comprising a fumaric acid ester |
| US20060121112A1 (en) * | 2004-12-08 | 2006-06-08 | Elan Corporation, Plc | Topiramate pharmaceutical composition |
| US20070298098A1 (en) * | 2005-02-16 | 2007-12-27 | Elan Pharma International Limited | Controlled Release Compositions Comprising Levetiracetam |
| ITBO20050123A1 (en) * | 2005-03-07 | 2005-06-06 | Alfa Wassermann Spa | GASTRORESISTIC PHARMACEUTICAL FORMULATIONS CONTAINING RIFAXIMINA |
| US20060222700A1 (en) * | 2005-04-05 | 2006-10-05 | Groenewoud Pieter J | Tablet and capsule form of liquid active ingredient |
| WO2006110807A1 (en) * | 2005-04-12 | 2006-10-19 | Elan Pharma International Limited | Controlled release compositions comprising a cephalosporin for the treatment of a bacterial infection |
| US20100136106A1 (en) * | 2005-06-08 | 2010-06-03 | Gary Liversidge | Modified Release Famciclovir Compositions |
| US8865197B2 (en) * | 2005-09-06 | 2014-10-21 | Israel Oceanographic And Limnological Research Ltd. | Food formulation for aquatic animals with integrated targeted delivery of bioactive agents |
| US8778924B2 (en) * | 2006-12-04 | 2014-07-15 | Shionogi Inc. | Modified release amoxicillin products |
| US8357394B2 (en) | 2005-12-08 | 2013-01-22 | Shionogi Inc. | Compositions and methods for improved efficacy of penicillin-type antibiotics |
| US8299052B2 (en) | 2006-05-05 | 2012-10-30 | Shionogi Inc. | Pharmaceutical compositions and methods for improved bacterial eradication |
| ITMI20061692A1 (en) | 2006-09-05 | 2008-03-06 | Alfa Wassermann Spa | USE OF POLYOLS TO OBTAIN STYLE POLYMORPHIC FORMS OF RIFAXIMINA |
| WO2008085484A2 (en) * | 2006-12-28 | 2008-07-17 | Jacobus Pharmaceutical Company, Inc. | Treatment of inflammatory bowel disease with enteric coated formulations comprising 5-aminosalicylic acid or 4-aminosalicylic acid |
| RU2013106514A (en) * | 2007-10-12 | 2015-03-10 | Такеда Фармасьютикалз Норт Америка, Инк. | METHODS FOR TREATING GASTROINTESTINAL DISORDERS INDEPENDENTLY ON FOOD CONSUMPTION |
| PL2493471T3 (en) | 2009-10-26 | 2020-10-19 | Borody | Novel enteric combination therapy |
| RU2014141201A (en) | 2012-03-29 | 2016-05-20 | ТЕРАБАЙОМ, ЭлЭлСи | COMPOSITIONS FOR GASTROINTESTINAL SITE-SPECIFIC ORAL VACCINATION, MANIFESTING ACTIVITY IN THE IOLIC GUT AND APPENDIX |
| US20140141075A1 (en) | 2012-11-21 | 2014-05-22 | Warner Chilcott Company, Llc | 5-aminosalicylic acid capsule formulation |
| US9180104B2 (en) | 2013-03-13 | 2015-11-10 | Tris Pharma, Inc. | Benzonatate modified release solid tablets and capsules |
| CN105188677A (en) | 2013-03-13 | 2015-12-23 | 特瑞斯制药股份有限公司 | Benzonatate modified release solid tablets and capsules |
| JP6464142B2 (en) | 2013-03-14 | 2019-02-06 | セラバイオーム，エルエルシー | Targeted gastrointestinal delivery of probiotic organisms and / or therapeutic agents |
| AU2014239683B2 (en) | 2013-03-15 | 2018-05-17 | Allergan Pharmaceuticals International Limited | Mesalamine pharmaceutical composition with multiple dosage elements for reduced delivery variability |
| US20200181649A1 (en) * | 2016-07-14 | 2020-06-11 | University Of Delaware | Hybrid formulation of responsive polymeric nanocarriers for therapeutic and diagnostic delivery |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2021409B (en) * | 1977-05-25 | 1982-09-22 | Fisons Ltd | Pharmaceutical composition |
| US4250166A (en) * | 1977-05-27 | 1981-02-10 | Shionogi & Co., Ltd. | Long acting preparation of cefalexin for effective treatments of bacterial infection sensitive to cefalexin |
| FR2426477A1 (en) * | 1978-05-26 | 1979-12-21 | Monsanto Co | FIRE DELAY COMPOSITION INCLUDING IN PARTICULAR AMMONIUM SULPHATE AND A CARBOXYALKYL OR HYDROXYALKYL ETHER OF A POLYGALACTOMANNAN |
| JPS57500432A (en) * | 1980-03-20 | 1982-03-11 | ||
| SE8003805L (en) * | 1980-05-21 | 1981-11-22 | Haessle Ab | A PHARMACEUTICAL PREPARATION WITH IMPROVED EMISSION PROPERTY |
| ZA825384B (en) * | 1981-07-31 | 1983-05-25 | Tillott J B Ltd | Orally administrable pharmaceutical compositions |
| DK150008C (en) * | 1981-11-20 | 1987-05-25 | Benzon As Alfred | PROCEDURE FOR THE PREPARATION OF A PHARMACEUTICAL ORAL POLYDEPOT PREPARATION |
| IT1230576B (en) * | 1988-10-20 | 1991-10-28 | Angeli Inst Spa | ORAL PHARMACEUTICAL FORMULATIONS WITH SELECTIVE LIBERATION IN THE COLON |
| IL92343A0 (en) * | 1988-12-20 | 1990-07-26 | Gist Brocades Nv | Granulate for multiparticulate controlled release oral compositions,their preparation and oral pharmaceutical compositions containing them |
| ES2077023T3 (en) * | 1989-03-10 | 1995-11-16 | Yamanouchi Pharma Co Ltd | COATING MATERIAL THAT CONTROLS THE RELEASE OF A MEDICINAL PRODUCT FOR FORMULATIONS OF PROLONGED ACTIVITY. |
| JPH0334929A (en) * | 1989-06-29 | 1991-02-14 | Teikoku Seiyaku Kk | Oral administration composition for treating ulcerative colitis and crohn's disease |
| US5260071A (en) * | 1989-12-18 | 1993-11-09 | Lemelson Jerome H | Drug units and methods for using same |
| JPH064531B2 (en) * | 1990-06-04 | 1994-01-19 | アイセロ化学株式会社 | Colon disintegrating hard capsule |
-
1991
- 1991-02-22 GE GEAP19912613A patent/GEP19971086B/en unknown
- 1991-02-22 GB GB9103795A patent/GB2253346A/en not_active Withdrawn
-
1992
- 1992-02-21 IL IL10103692A patent/IL101036A/en not_active IP Right Cessation
- 1992-02-21 AT AT92905384T patent/ATE129893T1/en not_active IP Right Cessation
- 1992-02-21 CZ CS931626A patent/CZ281792B6/en not_active IP Right Cessation
- 1992-02-21 JP JP4505041A patent/JP2958116B2/en not_active Expired - Fee Related
- 1992-02-21 EP EP92905384A patent/EP0572486B1/en not_active Expired - Lifetime
- 1992-02-21 WO PCT/GB1992/000318 patent/WO1992014452A1/en active IP Right Grant
- 1992-02-21 ES ES92905384T patent/ES2079183T3/en not_active Expired - Lifetime
- 1992-02-21 AU AU12795/92A patent/AU652032B2/en not_active Ceased
- 1992-02-21 IN IN149DE1992 patent/IN179089B/en unknown
- 1992-02-21 KR KR1019930702488A patent/KR100220322B1/en not_active IP Right Cessation
- 1992-02-21 DK DK92905384.1T patent/DK0572486T3/en active
- 1992-02-21 HU HU9302379A patent/HU219449B/en not_active IP Right Cessation
- 1992-02-21 DE DE69205971T patent/DE69205971T2/en not_active Expired - Lifetime
- 1992-02-21 US US08/107,744 patent/US5401512A/en not_active Expired - Lifetime
- 1992-02-21 YU YU17892A patent/YU17892A/en unknown
- 1992-02-21 CA CA002104686A patent/CA2104686C/en not_active Expired - Lifetime
- 1992-02-21 IE IE920548A patent/IE74225B1/en not_active IP Right Cessation
- 1992-02-21 NZ NZ241687A patent/NZ241687A/en not_active IP Right Cessation
-
1993
- 1993-08-20 NO NO932979A patent/NO307405B1/en not_active IP Right Cessation
- 1993-08-20 FI FI933680A patent/FI105255B/en not_active IP Right Cessation
-
1995
- 1995-12-19 GR GR950403588T patent/GR3018455T3/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2104686C (en) | Delayed release oral dosage forms for treatment of intestinal disorders | |
| US4728512A (en) | Formulations providing three distinct releases | |
| CA1172570A (en) | Orally administrable pharmaceutical compositions | |
| US4904476A (en) | Formulations providing three distinct releases | |
| US4794001A (en) | Formulations providing three distinct releases | |
| JP3194974B2 (en) | Target controlled release drug | |
| EP0825854B1 (en) | Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery | |
| EP0827398B1 (en) | Pharmaceutical dosage form for colonic delivery | |
| CN101287443B (en) | Pulse releasing system controlled by pH, preparation method and application thereof | |
| BG65443B1 (en) | Enteric coated pharmaceutical composition containing didanosine | |
| BG65398B1 (en) | Enteric coated pharmaceutical composition and method of manufacturing it | |
| AU732210B2 (en) | Colonic delivery of weak acid drugs | |
| KR20000053326A (en) | Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery | |
| AU627335B2 (en) | Aspirin granules with gastroprotectant coating | |
| RU2412694C2 (en) | pH-CONTROLLED PULSE DELIVERY SYSTEMS, METHODS FOR PRODUCING AND USING THEREOF | |
| Kaur et al. | Recent approaches for colon drug delivery | |
| Shah et al. | Enteric coating for colonic delivery | |
| MXPA99003093A (en) | Colonic delivery of weak acid drugs | |
| WO1994007503A1 (en) | Enteric preparations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed | ||
| MKEC | Expiry (correction) |
Effective date: 20121202 |